Transcript
A (0:00)
Foreign welcome to Coruscant Technologies, home of the Digital Executive Podcast. Welcome to the Digital Executive. Today's guest is Christopher Cresilius. Christopher Cresilius is a dynamic entrepreneur and visionary, founder of Axon Dao, seamlessly blending his diverse expertise in technology, health and the arts. Holding a bachelor's degree in business and fine arts from High Point University and an associate's degree in auto Engineering from Pulsail University, Christopher has consistently championed the integration of seemingly disparate fields. His passions include DSCI, DAOs, health tech, generative art, clinical research, and neuroscience, with a particular focus on the intersection of technology, health, art, data and sound frequencies. Well, good afternoon, Chris. Welcome to the show.
B (0:54)
Thanks for having me, Brian.
A (0:56)
Absolutely. I appreciate you making the time today, hailing out of that D.C. area. I'm in Kansas City, so love doing a little bit of traversing across the country today. Chris, I'm going to jump right into your first question. Your background spans technology, health and the arts. How have these diverse fields influenced your approach to founding and leading Axon Dao?
B (1:16)
Good question. I think that really given me the creative, almost holistic approach to discovering a solution to problems. Not taking the traditional means, I think has given us a different perspective and understanding. Being from the arts and creative side to technical and very professional, you still have the human element that I think people oversee. And I think taking this approach a little more holistic, a little more creative, a little more scientific approach is what's needed in this day and age.
A (1:51)
Thank you. And I think diversity, right? We both have diverse backgrounds in where we've worked, industries and that sort of thing. But highlighting those three things, being holistic, creative, and of course, a little bit of scientific there makes all the world of a difference. So I appreciate that. And Chris, my next question for you. Exxon Dao aims to democratize medical science through decentralization, challenging traditional pharmaceutical monogam monopolies. Could you elevate on how Axon Dow plans to achieve this transformation?
B (2:22)
Yeah, the idea that we work with a lot of folks that are currently in the medical field, they're in the traditional system. You can tell there's a lot of frustrations, bottlenecks. We began as to understand where those problems are and how technology can solve those problems. Now technology is rapidly advanced over the past 10 years. We've been at it for about 12, maybe a little more. But to see the bottlenecks, the systems, I think that now there's so much more truth and tools to give you that truth about your own health, about how things Work in general that people are searching for something that's going to offer them that and I think the time is right with technology, with the apparent need and especially you do a general survey of anyone in the medical industry, I think they can give you a list of 10 things that they want to scratch their head about. So we are just always going to take a pragmatic approach. This is never a find a solution and walk away. This is always going to be something that we work towards. Our strategy is really always taking the scientific approach and never just settling for what we think is correct. Because things are going to continue to change and we want to change with it. But to our advantage is that we are independent. We aren't governed or managed by any VC or big tech or big pharma investor. So we can allow ourselves to take that pragmatic perspective of like how to solve the problem by eliminating all the bureaucratic issues that may be an institution who's unfortunately having to had deal with those things for so long that we can be more nimble. And that's really our, I think our advantage to the most point.
